companydata.dkcompanydata.dk

Y-mAbs Therapeutics A/S: Financial statements 2022

CVR: 37053678

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 82,332,358 and a net result of DKK -85,685,825 compared with DKK -42,087,769 the year before. That is an increase of 21.9% compared with the year before. Equity in the 2022 report amounted to DKK -84,940,941. The company had 101 employees in the financial year.

Gross Profit
DKK 82,332,358
Profit/Loss
DKK -85,685,825
Equity
DKK -84,940,941
Total Assets
DKK 22,905,762
Employees
101

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-82.3M-85.7M-84.9M101
2021-67.5M-42.1M-39.3M88
2020-82.4M-1.2M2.8M62
2019-52M-2.6M4M36
2018-28.6M-4.2M1.6M19

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Y-mAbs Therapeutics A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Y-mAbs Therapeutics A/S: The 2021 annual report is outJun 30, 2022

Y-mAbs Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 67,549,569, and the net result was DKK -42,087,769.

Johan Ernst Wedell-Wedellsborg joins the board of Y-mAbs Therapeutics A/SMay 12, 2022

As of May 12, 2022, Johan Ernst Wedell-Wedellsborg has joined the board of directors of Y-mAbs Therapeutics A/S.

Thomas Gad joins the board of Y-mAbs Therapeutics A/SMay 12, 2022

As of May 12, 2022, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.

Bo Kruse joins the board of Y-mAbs Therapeutics A/SMay 12, 2022

As of May 12, 2022, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.

Claus Juan Møller-San Pedro leaves the board of Y-mAbs Therapeutics A/SMay 12, 2022

As of May 12, 2022, Claus Juan Møller-San Pedro has left the board of directors of Y-mAbs Therapeutics A/S.

Thomas Gad joins Y-mAbs Therapeutics A/S as adm. dir.May 12, 2022

As of May 12, 2022, Thomas Gad is registered as adm. dir. of Y-mAbs Therapeutics A/S.

Claus Juan Møller-San Pedro steps down as director of Y-mAbs Therapeutics A/SMay 12, 2022

As of May 12, 2022, Claus Juan Møller-San Pedro has stepped down as director of Y-mAbs Therapeutics A/S.

Thomas Gad leaves the board of Y-mAbs Therapeutics A/SMay 11, 2022

As of May 11, 2022, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.

Bo Kruse leaves the board of Y-mAbs Therapeutics A/SMay 11, 2022

As of May 11, 2022, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.

About Y-mAbs Therapeutics A/S

Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.

Source: annual report 2025, Danish Business Authority